{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:24:13Z","timestamp":1794885853692,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000179","name":"Office of the Director","doi-asserted-by":"publisher","award":["S10OD026959"],"award-info":[{"award-number":["S10OD026959"]}],"id":[{"id":"10.13039\/100000179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010637","name":"Huntsman Cancer Foundation","doi-asserted-by":"publisher","award":["T32TR004394"],"award-info":[{"award-number":["T32TR004394"]}],"id":[{"id":"10.13039\/100010637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010637","name":"Huntsman Cancer Foundation","doi-asserted-by":"publisher","award":["R01CA121118"],"award-info":[{"award-number":["R01CA121118"]}],"id":[{"id":"10.13039\/100010637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xcrm.2025.101943","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:34:11Z","timestamp":1738924451000},"page":"101943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Combined inhibition of focal adhesion kinase and RAF\/MEK elicits synergistic inhibition of melanoma growth and reduces metastases"],"prefix":"10.1016","volume":"6","author":[{"given":"Jared","family":"Almazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tursun","family":"Turapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly A.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Paulina","family":"Medellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MiKaela N.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennie L.","family":"Parkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Pachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-6032","authenticated-orcid":false,"given":"Sheri L.","family":"Holmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.101943_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113287","article-title":"Stereotactic radiosurgery and anti-PD-1\u00a0+ CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases","volume":"192","author":"Dohm","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.101943_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","article-title":"Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases","volume":"23","author":"Dai","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101943_bib3","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib4","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 Activity Promotes Development of Malignant Melanoma","volume":"64","author":"Stahl","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1158\/1541-7786.MCR-18-1372","article-title":"AKT1(E17K) Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis","volume":"17","author":"Kircher","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/pcmr.12644","article-title":"Dual MEK\/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma","volume":"31","author":"Algazi","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.35200","article-title":"A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers","volume":"130","author":"Algazi","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.101943_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1535-7163.MCT-23-0474","article-title":"Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression","volume":"23","author":"Parkman","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.101943_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031726","article-title":"FAK in Cancer: From Mechanisms to Therapeutic Strategies","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.101943_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-17-0561","article-title":"Wnt\/beta-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.101943_bib11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.101943_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2025.101943_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144250","article-title":"Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2025.101943_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.101943_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41416-024-02727-2","article-title":"Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer","volume":"131","author":"Yoshimura","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.101943_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70210","article-title":"Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer","volume":"13","author":"Hartwich","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2025.101943_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2024.04.010","article-title":"Preclinical in\u00a0vitro and in\u00a0vivo activity of the RAF\/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas","volume":"187","author":"Demirkiran","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2025.101943_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.101943_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2025.101943_bib20","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: A phase 2 study of avutometinib (VS-6766)\u00a0\u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"41","author":"Banerjee","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101943_bib21","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib22","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.101943_bib24","doi-asserted-by":"crossref","first-page":"TPS5615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5615","article-title":"ENGOT-ov60\/GOG-3052\/RAMP 201: A phase 2 study of VS-6766 (RAF\/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"40","author":"Banerjee","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101943_bib25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12498","article-title":"The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations","volume":"29","author":"Meeth","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.101943_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","article-title":"AKT1 Activation Promotes Development of Melanoma Metastases","volume":"13","author":"Cho","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.101943_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109956","article-title":"Glowing head\" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts","volume":"9","author":"Day","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.101943_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/d41573-023-00202-w","article-title":"FDA approves first-in-class AKT inhibitor","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.101943_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molcel.2009.06.013","article-title":"FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST","volume":"35","author":"Zheng","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.101943_bib31","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","article-title":"Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma","volume":"27","author":"Paradis","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib32","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.3390\/cancers15082280","article-title":"FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma","volume":"15","author":"Tarin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.101943_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nrm.2017.87","article-title":"Mechanobiology of YAP and TAZ in physiology and disease","volume":"18","author":"Panciera","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.101943_bib34","doi-asserted-by":"crossref","unstructured":"Lubrano, S., Faraji, F., Cervantes-Villagrana, R.D., Ramirez, S., Arang, N., Officer, A., Rigiracciolo, D.C., Quiroz, P.Y.A., Bacchiocchi, A., Halaban, R., et al. (2024). Abstract 4745: A novel combination therapy targeting RAF,\u00a0MEK and FAK to overcome skin cutaneous melanoma treatment resistance. Cancer Res. 84, 4745. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-4745","DOI":"10.1158\/1538-7445.AM2024-4745"},{"key":"10.1016\/j.xcrm.2025.101943_bib35","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/JVI.78.9.4914-4916.2004","article-title":"Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector","volume":"78","author":"Bromberg-White","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2025.101943_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1755-148X.2010.00717.x","article-title":"Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a\/Arflox\/lox mice","volume":"23","author":"VanBrocklin","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.xcrm.2025.101943_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","author":"Dankort","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2025.101943_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature07443","article-title":"p53 and Pten control neural and glioma stem\/progenitor cell renewal and differentiation","volume":"455","author":"Zheng","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.101943_bib39","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/sj.bjc.6604637","article-title":"A novel AKT3 mutation in melanoma tumours and cell lines","volume":"99","author":"Davies","year":"2008","journal-title":"Br. J. Cancer"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:37:44Z","timestamp":1772483864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666379125000163"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101943","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined inhibition of focal adhesion kinase and RAF\/MEK elicits synergistic inhibition of melanoma growth and reduces metastases","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101943"}}